Navigation Links
Genzyme to Build New R&D Center in Beijing
Date:4/22/2008

Environmentally Responsible Site to Significantly Increase Company's

Presence in China

CAMBRIDGE, Mass., April 22 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) announced today that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion and commitment to establishing a long-term presence in China.

The new facility will be used for research and development activities involving many of Genzyme's key areas of focus, including orthopedics, transplant and immune disease, oncology, endocrinology and cardiovascular disease. The facility, which will feature an innovative green design, will also include laboratory-scale operations for the MACI(R) (matrix-induced autologous chondrocyte implantation) cell therapy and polyclonal antibody operations.

"This new site represents a major step forward in our effort to improve the lives of patients in China by introducing innovative new medical products," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "As we expand our presence in China, we look forward to making a significant contribution to the growth of the country's life sciences industry."

Genzyme already markets Synvisc(R) (hylan G-F 20) and Thymoglobulin(R) (anti-thymocyte globulin rabbit) in China, and is preparing to introduce additional products next year. The company also has a pilot program at Beijing Wujing Hospital for the cell therapy product MACI. Genzyme currently has 25 employees working in offices in Beijing and Shanghai.

Since 1999, Genzyme has provided its rare genetic disease treatment Cerezyme(R) (imiglucerase for injection) free of charge to Chine
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Genzyme Provides Update on Myozyme(R) Manufacturing
2. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
3. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
4. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
5. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
6. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
7. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
8. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
9. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014  Last week, Representatives ... (D-NC) took a bold bipartisan step on ... the OPEN Act. Original co-sponsors of the legislation ... Act will incentivize drug makers and innovators to ... and pediatric cancers, which opens the door to ...
(Date:11/24/2014)... MD (PRWEB) November 24, 2014 ... underrepresented patient populations into clinical trials at its ... , “Continental was created with the idea ... play a fundamental role in medical advances," said ... Tuskegee syphilis experiment to the immortal cell line ...
(Date:11/23/2014)... November 23, 2014 Apiscent Labs, ... of fine chemical ingredients to the global pharmaceutical ... of its new website, Apiscent.com. , The Apiscent.com ... Labs, clean design, easy navigation, rotating images and ... Labs stand out. , The company’s ...
(Date:11/22/2014)... RURO, Inc., a leading LIMS, ... Limfinity® version 5.1.4. , RURO’s deployment teams have ... ever in RURO’s 8 year history. Many deployments ... Limfinity® version 5.1.4 is the perfect example – ... fixes! , Limfinity® 5.1.4 release highlights – more ...
Breaking Biology Technology:OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3RURO Announces Limfinity® version 5.1.4 2
... 2009A team of Los Alamos researchers led by Victor ... multiple electronsis a real phenomenon in tiny semiconductor crystals ... that mimic carrier multiplication. The research, explained in a ... shows the possibility of solar cells that create more ...
... Personalized Medicine Conference is bringing together the wide variety of stakeholders ... opportunities and challenges facing those involved in the development and realization ... ... 10, 2009 -- Arrowhead,s 2009 Personalized Medicine Conference is ...
... System Will Continue to Fuel Growth and Generate CashNEW YORK, ... Vice President James C. Borel said today he expects DuPont ... share by at least 1 to 2 points in 2009 ... DuPont Agriculture & Nutrition segment an average of at least ...
Cached Biology Technology:Research highlights potential for improved solar cells 2Research highlights potential for improved solar cells 3The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference 2The Biggest Names in the Field of Personalized Medicine to Speak at Arrowhead's Upcoming 2009 Personalized Medicine Conference 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 2DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 3DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 4DuPont Expects Increased Global Seed Corn Share, Continued Agriculture Earnings Growth 5
(Date:11/7/2014)... Auguste, associate professor, biomedical engineering, in the Grove ... New York, have identified a molecule that could ... most aggressive forms of breast cancer. , Triple ... rate owing to aggressive proliferation and metastasis and ... Auguste,s team, discovered the overexpression of intercellular adhesion ...
(Date:11/6/2014)... A groundbreaking paper from a team of Florida State ... how plants could adapt to and survive environmental swings ... in the latest issue of the journal The ... complex of DNA and proteins) is organized in a ... some genes are turned on and others are turned ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
... Academic Affairs John Wiecha, MD, MPH, in the Department ... Health (NIH) American Recovery & Reinvestment Act (ARRA) Challenge ... valued at more than $950,000 will fund a study ... diabetes. The health education will be conducted either ...
... years ago, vertebrates lacked the ability to chew their food. ... a flexible, fused basket of cartilage. This week, an ... the University of Colorado at Boulder published evidence that three ... development of jaws in higher vertebrates. The finding is ...
... adverts, the secret of fertility might not be eternal youth. ... Research at the Consejo Superior de Investigaciones Cientficas in Seville, ... have evolved to protect their seeds. His research is published ... Botany ( http://dx.doi.org/10.1093/aob/mcq160 ). Prof. Herrera said: "No ...
Cached Biology News:Wiecha receives grant to study face-to-face vs. virtual health education for African-American women 2Genetic clues to evolution of jaws in vertebrates unearthed by CU-led team 2
HLA II DG+DR+DP Monoclonal Antibody, Purified, Unconjugated, Clone: IQU9 This antibody is specific for the monomorphic determinant of the HLA Class II beta chains of the human MHC (28 kDa)....
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Phospho-MEF2A(Thr312)...
Tube-O-DIALYZER Floats, small....
Biology Products: